Mindbreeze Introduces the Medical Cockpit
24.5.2018 11:30:00 EEST | Business Wire | Press release
Mindbreeze introduces the Medical Cockpit ̶ an intelligent solution for the semantic analysis and networked searching of medical data.
With the Medical Cockpit, information from all types of structured and unstructured medical documents – such as doctor’s letters, test results and findings, laboratory and OR reports – can be specifically filtered and processed for medical personnel.
The system provides employees with a quick, subject-specific overview of the current patient based on their individual access rights, and extracts diagnoses, symptoms, and medications from the many different documents, resulting in enormous time savings.
“A tool that is able to collect, analyze, and make the necessary information available in a customized way translates into improved treatment quality in this sector as well as a dramatic reduction in the workload for medical staff. Our Medical Cockpit provides a swift and comprehensive view of all patient data and extracts important key information such as diagnoses, symptoms, and medication from documents,” explains Dr. Adolf Sonnleitner, MD, who heads the Healthcare Division at Mindbreeze.
The Medical Cockpit is already being used in a number of hospitals in German-speaking countries.
Medical Cockpit:
By semantically linking service catalogs, diagnosis catalogs, as well as synonym and jargon lists, the Medical Cockpit understands medical terminology and syntax and can reliably identify specific patterns in findings, diseases, and medication. Depending on the subject and occupational group (physician, caregiver, therapist), users can call up a compilation of all the data they currently require – such as the complete subject-specific information about a patient, and obtain a rapid overview of even the most complex cases.
About Mindbreeze
Mindbreeze is a leading provider of appliances and cloud services for enterprise search, applied artificial intelligence, and knowledge management. The Mindbreeze insight engine understands information and provides a consolidated view of corporate knowledge – regardless of where (data sources) and how (structured, unstructured) the data is stored. Through a global network of partners, Mindbreeze covers all time zones.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180524005483/en/
Contact information
Mindbreeze
Ulrike Kogler
+43 732 606162-0
pr@mindbreeze.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 14:05:00 EEST | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe joins Veristat as Chief Human Resources Officer (CHRO). After spending his early career in academia working on clinical trials at Harvard University, Dr. Su took a biostatistical leaders
Bacardi Takes Full Ownership of TEELING® Irish Whiskey23.6.2026 14:00:00 EEST | Press release
Bacardi Limited has announced the completion of a transaction that makes the family-owned company the sole owner of the Teeling Whiskey Company and the TEELING® Irish whiskey brand. Founders Jack and Stephen Teeling will remain a part of the brand, shaping its future and driving growth for the long term as strategic advisors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623858211/en/ Three expressions of Teeling Irish Whiskey: Single Grain, Small Batch and Single Malt Today’s announcement follows the successful relationship the two companies have enjoyed since Bacardi acquired a minority stake in the Dublin-based whiskey company in 2017. Bacardi subsequently increased its stake to become the majority shareholder in 2022. “TEELING is the perfect fit for Bacardi,” says Mahesh Madhavan, Chief Executive Officer, Bacardi Limited. “The brand stands for quality, craftsmanship and a fearless approach to the category with fresh
Bending Spoons S.p.A. announces launch of initial public offering23.6.2026 13:15:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the launch of its initial public offering (the “IPO”) of its ordinary shares. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 are being offered by Bending Spoons and 23,572,375 are being offered by certain selling shareholders (the “Selling Shareholders”). In connection with the offering, Bending Spoons and the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and an additional 3,451,626 ordinary shares from the Selling Shareholders at the IPO price, less underwriting discounts and commissions. The IPO price is currently estimated to be between $26.00 and $28.00 per share. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint l
WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future23.6.2026 13:00:00 EEST | Press release
Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today revealed topline findings from a forthcoming study at Journal House during the Cannes Lions International Festival of Creativity. The study delivered a clear takeaway for global businesses: human cognition must be the absolute forefront of the modern corporate landscape. The findings show that uniquely human skills are vital, non-replicable, and increasingly valuable in an AI-embedded future, with creative empathy and critical thinking among the most distinctive workplace advantages. Surveying over 2,500 business professionals across the United States, United Kingdom, Italy, South Africa and Brazil, the joint initiative is the largest-scale research program ever conducted by WSJ Intelligence. The full survey results will be released in September in a deep-dive report on the growing value of human cognition. “At
Bitcoin Suisse Receives MiCAR License and Launches European Expansion23.6.2026 12:37:00 EEST | Press release
After more than a decade as Switzerland's crypto pioneer, the Bitcoin Suisse Group ("Bitcoin Suisse") is expanding across Europe. Its European entity, Bitcoin Suisse (Europe) AG, founded in 2018, has been granted a license as a Crypto Asset Service Provider (CASP) under MiCAR by the Liechtenstein Financial Market Authority (FMA), building on its long-standing registration under the Token and TT Service Provider Act (TVTG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622188006/en/ left: Andrej Majcen, Co-Founder and Group CEO of the Bitcoin Suisse Group; right: Roman Przibylla, CEO of Bitcoin Suisse (Europe) AG Across Europe, Bitcoin Suisse operates with a clear ambition: to be the first choice for high-net-worth individuals, corporates and institutional investors. This ambition is built on more than a decade of operational experience, proven across multiple market cycles in which the company’s business model has consis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom